Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:HCM NASDAQ:IMTX NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$40.39+1.9%$32.56$16.50▼$43.58$3.52BN/A11,795 shs7,108 shsHCMHUTCHMED$17.59+0.4%$15.15$11.51▼$21.50$3.07B0.5291,548 shs25,725 shsIMTXImmatics$6.00-3.4%$5.58$3.30▼$13.09$729.30M0.81683,311 shs187,803 shsIMVTImmunovant$17.91-2.0%$15.86$12.72▼$34.47$3.06B0.631.22 million shs1.03 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+5.62%+12.57%+115.76%+4,038,999,900.00%HCMHUTCHMED0.00%+9.66%+14.00%+27.83%-8.05%IMTXImmatics0.00%+0.50%+2.56%+40.85%-51.18%IMVTImmunovant0.00%-1.21%+12.93%+18.22%-40.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED0.6778 of 5 stars1.03.00.00.00.60.01.9IMTXImmatics3.0852 of 5 stars3.64.00.00.03.51.70.0IMVTImmunovant1.5585 of 5 stars3.40.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AHCMHUTCHMED 2.00Hold$19.008.02% UpsideIMTXImmatics 3.20Buy$14.67144.44% UpsideIMVTImmunovant 2.82Moderate Buy$36.30102.68% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, IMVT, HCM, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.005/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M3.59N/AN/A$0.48 per share84.15HCMHUTCHMED$630.20M4.87$0.29 per share61.24$4.43 per share3.97IMTXImmatics$144.15M5.06$0.24 per share24.56$5.12 per share1.17IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AHCMHUTCHMED$37.73MN/A0.0012.05N/AN/AN/AN/A8/7/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)Latest IMTX, IMVT, HCM, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q1 2025IMTXImmatics-$0.38N/AN/AN/A$13.05 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26HCMHUTCHMED0.082.832.70IMTXImmaticsN/A10.2810.28IMVTImmunovantN/A11.1611.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AHCMHUTCHMED8.82%IMTXImmatics64.41%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AHCMHUTCHMED3.60%IMTXImmatics3.30%IMVTImmunovant1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/AHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMTXImmatics260121.55 million117.54 millionOptionableIMVTImmunovant120171.07 million167.99 millionOptionableIMTX, IMVT, HCM, and AAPG HeadlinesRecent News About These CompaniesAll You Need to Know About Immunovant (IMVT) Rating Upgrade to BuyJuly 16, 2025 | zacks.comWall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?July 16, 2025 | zacks.comEmerald Advisers LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)July 14, 2025 | marketbeat.comImmunovant (IMVT) chief technology officer Stout sells $26k in stockJuly 13, 2025 | investing.comPrincipal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT)July 13, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $19,998.40 in StockJuly 12, 2025 | insidertrades.comImmunovant (NASDAQ:IMVT) Rating Increased to Hold at The Goldman Sachs GroupJuly 12, 2025 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Insider Michael Geffner Sells 1,160 SharesJuly 11, 2025 | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CTO Sells 1,519 Shares of StockJuly 11, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Coverage Initiated by Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 7, 2025 | marketbeat.comLifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PTJuly 6, 2025 | msn.comImmunovant, Inc. (IMVT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comImmunovant (NASDAQ:IMVT) Stock Updated Nasdaq CompositeJune 23, 2025 | kalkinemedia.comKZacks Research Comments on Immunovant FY2028 EarningsJune 23, 2025 | marketbeat.comTracking Baker Brothers Portfolio - Q1 2025 UpdateJune 17, 2025 | seekingalpha.comImmunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)June 13, 2025 | seekingalpha.comImmunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?June 2, 2025 | zacks.comIMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in FocusMay 30, 2025 | zacks.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 29, 2025 | tipranks.comImmunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The FenceMay 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, IMVT, HCM, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$40.39 +0.77 (+1.94%) As of 07/18/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.HUTCHMED NASDAQ:HCM$17.59 +0.07 (+0.40%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$17.57 -0.02 (-0.14%) As of 07/18/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immatics NASDAQ:IMTX$6.00 -0.21 (-3.38%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.86 -0.15 (-2.42%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Immunovant NASDAQ:IMVT$17.91 -0.37 (-2.02%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$18.03 +0.12 (+0.67%) As of 07/18/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
